Abstract
Ischemic brain injury can be anticipated in a number of clinical settings such as procedures associated with a high-risk for stroke, patients with transient ischemic attacks or minor strokes who are at substantial risk for early recurrence and patients with multiple vascular risk factors with an enhanced risk for ischemic stroke over many years. In such high-risk settings, it may be possible to employ neuroprotective drugs prophylactically to reduce the extent and clinical consequences of ischemic events. The concept of prophylactic neuroprotection can be envisioned for varying time periods and with a variety of drug classes depending upon the target population. This review will focus on which target populations should be considered for prophylactic neuroprotection trials and which drugs might be used in such trials.
Keywords: Neuroprotection, prophylactic, statins, infarct, stroke
Current Drug Targets
Title: Prophylactic Neuroprotection
Volume: 8 Issue: 7
Author(s): Sean I. Savitz and Marc Fisher
Affiliation:
Keywords: Neuroprotection, prophylactic, statins, infarct, stroke
Abstract: Ischemic brain injury can be anticipated in a number of clinical settings such as procedures associated with a high-risk for stroke, patients with transient ischemic attacks or minor strokes who are at substantial risk for early recurrence and patients with multiple vascular risk factors with an enhanced risk for ischemic stroke over many years. In such high-risk settings, it may be possible to employ neuroprotective drugs prophylactically to reduce the extent and clinical consequences of ischemic events. The concept of prophylactic neuroprotection can be envisioned for varying time periods and with a variety of drug classes depending upon the target population. This review will focus on which target populations should be considered for prophylactic neuroprotection trials and which drugs might be used in such trials.
Export Options
About this article
Cite this article as:
Sean I. Savitz and Marc Fisher , Prophylactic Neuroprotection, Current Drug Targets 2007; 8 (7) . https://dx.doi.org/10.2174/138945007781077382
DOI https://dx.doi.org/10.2174/138945007781077382 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacogenetics and Pharmacotherapy of Military Personnel Suffering from Post-traumatic Stress Disorder
Current Neuropharmacology Therapeutic Gene Products Delivery by Neuron Stem Cells
Current Pharmaceutical Biotechnology Nitric Oxide Synthase as a Target for the Prevention of Hypoxic-Ischemic Newborn Brain Damage
Current Enzyme Inhibition Post Traumatic Lesion absence of β-Dystroglycan-Immunopositivity in Brain Vessels Coincides with the Glial Reaction and the Immunoreactivity of Vascular Laminin
Current Neurovascular Research Methodological Considerations to Understand the Sensory Function of TRP Channels
Current Pharmaceutical Biotechnology Modulation of Neuro-Inflammation and Vascular Response by Oxidative Stress Following Cerebral Ischemia-Reperfusion Injury
Current Medicinal Chemistry Recent Advances in Pulmonary Hypertension Therapy
Recent Patents on Cardiovascular Drug Discovery Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews The Central Role of Angiotensin I-Converting Enzyme in Vertebrate Pathophysiology
Current Topics in Medicinal Chemistry Therapeutic Moderate Hypothermia and Fever
Current Pharmaceutical Design Apoptosis in Anthracycline Cardiomyopathy
Current Pediatric Reviews Recent progress in the development of anthrax vaccines
Recent Patents on Biotechnology Fabry Disease Cardiomyopathy: from Genes to Clinical Manifestations
Current Pharmaceutical Biotechnology A New Therapeutic Approach for Brain Delivery of Epigallocatechin Gallate: Development and Characterization Studies
Current Drug Delivery Transdermal Penetration Enhancers
Current Drug Therapy An Update on Drug Interactions with the Herbal Medicine Ginkgo biloba
Current Drug Metabolism Chelating Agents for Metal Intoxication
Current Medicinal Chemistry ERRATUM
Current Neuropharmacology A Comprehensive Review of Alzheimer’s Association with Related Proteins: Pathological Role and Therapeutic Significance
Current Neuropharmacology Insights on the Neuromodulatory Propensity of Selaginella (Sanjeevani) and its Potential Pharmacological Applications
CNS & Neurological Disorders - Drug Targets